Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
- Written by PR Newswire Asia - News Pronto RSS
 |
Durable Complete Metabolic Response Ongoing Since November 2025
All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively
No Treatment-Related Serious Adverse Events Observed
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited&n...